Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment
The DOI matches its Crossref record; 482 of the 482 references it cites were found in a registry or an index.
Abstract
Drug-induced calculi represent 1-2% of all renal calculi. The drugs reported to produce calculi may be divided into two groups. The first one includes poorly soluble drugs with high urine excretion that favour crystallisation in the urine. Among them, drugs used for the treatment of patients with human immunodeficiency, namely atazanavir and other protease inhibitors, and sulphadiazine used for the treatment of cerebral toxoplasmosis, are the most frequent causes. Besides these drugs, about 20 other molecules may induce nephrolithiasis, such as ceftriaxone or ephedrine-containing preparations in subjects receiving high doses or long-term treatment. Calculi analysis by physical methods including infrared spectroscopy or X-ray diffraction is needed to demonstrate the presence of the drug or its metabolites within the calculi. Some drugs may also provoke heavy intra-tubular crystal precipitation causing acute renal failure. Here, the identification of crystalluria or crystals within the kidney tissue in the case of renal biopsy is of major diagnostic value. The second group includes drugs that provoke the formation of urinary calculi as a consequence of their metabolic effects on urinary pH and/or the excretion of calcium, phosphate, oxalate, citrate, uric acid or other purines. Among such metabolically induced calculi are those formed in patients taking uncontrolled calcium/vitamin D supplements, or being treated with carbonic anhydrase inhibitors such as acetazolamide or topiramate. Here, diagnosis relies on a careful clinical inquiry to differentiate between common calculi and metabolically induced calculi, of which the incidence is probably underestimated. Specific patient-dependent risk factors also exist in relation to urine pH, volume of diuresis and other factors, thus providing a basis for preventive or curative measures against stone formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The topiramate component of phentermine HCl/topiramate ER decreases renal tubule reabsorption of HCO3 and decreases excretion of H, contributing to metabolic acidosis, and increased urinary pH, which may increase the risk of kidney stones [27], with the most specific reported composition being calcium phosphate stones [28].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [27]
In the citing paper
“Orlistat increases unabsorbed intestinal fat which binds to intestinal calcium, with less calcium available to bind to intestinal oxalate. This allows for increased intestinal oxalate absorption that may ultimately cause hyperoxaluria, promoting calcium oxalate stones [27].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [27]
Citations
Cites
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Calcium plus Vitamin D Supplementation and the Risk of Fractures
Jackson, R. D., LaCroix, A. Z., Gass, M., Wallace, R. B., Robbins, J., Lewis, C. E., Bassford, T., Beresford, S. A. A., Black, H. R., Blanchette, P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055218 · Cited by 1,883
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
The Pharmacology and Clinical Use of Methotrexate
Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J., & Chabner, B. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198311033091805 · Cited by 786
Campoli-Richards, D. M., Monk, J. P., Price, A., Benfield, P., Todd, P. A., & Ward, A. (1988) · Drugs · doi:10.2165/00003495-198835040-00003 · Cited by 749
Understanding and Managing Methotrexate Nephrotoxicity
Widemann, B. C., & Adamson, P. C. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-694 · Cited by 730
Mutations in CYP24A1 and Idiopathic Infantile Hypercalcemia
Schlingmann, K. P., Kaufmann, M., Weber, S., Irwin, A., Goos, C., John, U., Misselwitz, J., Klaus, G., Kuwertz-Bröking, E., Fehrenbach, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103864 · Cited by 691
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Research works printed but not linked: 18
- Réveillaud RJ, Daudon M. Les lithiases urinaires médicamenteuses. Sémin Uro-Néphrol. 1986;12:14–39.
- Nguyen Quy D, Daudon M. Infrared and Raman spectra of calculi. Paris: Elsevier; 1997.
- Daudon M. Méthodes d’analyse des calculs et des cristaux urinaires. Classification morpho-constitutionnelle des calculs. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences; 1989. p. 35–113.
- Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem. 1986;24:767–8.
- Daudon M, Estepa L, Viard JP, et al. Indinavir crystalluria in HIV-positive patients treated with indinavir sulfate. In: Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM, editors. Urolithiasis 2000, vol. I. Rondebosh: University of Cape Town; 2000. p. 335–7.
- Daudon M, Jungers P, Lacour B. Intérêt clinique de l’étude de la cristallurie. Ann Biol Clin. 2004;62:379–93.
- Daudon M, Estepa L, Labro B, et al. Infrared analysis of urinary calculi from animals [in French]. Eurobiol. 1998;236:243–55.
- Hammarsten G, Helldorff I, Magnusson W, et al. Dubbelsidiga njurstenar av kiselsyra efter bruk av silikathaltigt antacidum. Svensk Lakartiduing. 1953;50:1242–6.
- Hammarsten G. Terapi-inducerade urinvOagskonkrement. Opuscula Medica. 1958;3(1):19–22.
- Gaultier M, Bismuth C, Efthymiou ML, et al. Néphropathie tubulo-interstitielle aiguë au cours d’une intoxication par la glafénine. Nouv Presse Méd. 1975;1:3125.
- Volpe P, Peyrottes A, Lammle M, et al. Calcul urinaire de xanthine chez un patient porteur d’un syndrome de Lesch Nyhan. A propos d’un cas. Prog Urol. 1997;7(1):74–7.
- Cifuentes I, Bellanato J, Arquillué A, et al. Presencia de acido oxolinico en un calculo renal. Arch Esp Urol. 1986;39(5):369–73.
- Menzi P. Furadantin-Stein in einer Ureterozele. Helvet Chir. 1970;37(4/5):538–40.
- Zupancic M, Bukovec P. Complexation of magnesium (II) with ciprofloxacin and norfloxacin. Act Pharm. 1996;46:221–8.
- Parent X, Schieffer F. Felbamate crystalluria [in French]. Ann Biol Clin (Paris). 2010;68(5):609–13.
- Golematis B, Hatzitheofilou C, Dreiling DA, et al. The incidence of urolithiasis in pepticulcer patients. Am J Gastroenterol. 1977;68:367–71.
- Navas P, Grasset D. Anurie par lithiase urétérale urique bilatérale au cours d’un traitement par l’Amplivix. J Urol Néphrol. 1973;79:466–9.
- Matzkies F. Wirkungen und Nebenwirkungen von Benzbromaron bei der Initialbehandlung von Hyperurikämie und Gicht. Ergebnisse eines Feldversuches mit 3899 Patienten. Fortschr Med. 1978;96(32):1619–21.
Cited by
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
“As such, urine sediment examination for sulfa-drug–related crystals and casts is recommended to detect crystalline nephropathy when AKI develops (97,98).”
BackgroundRecent advances on the mechanisms of kidney stone formation (Review)
Wang, Z., Zhang, Y., Zhang, J., Deng, Q., & Liang, H. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4982 · Cited by 289
Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023
Shastri, S., Patel, J. D., Sambandam, K. K., & Lederer, E. D. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.03.017 · Cited by 303
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Multiple Pathways for Pathological Calcification in the Human Body
Vidavsky, N., Kunitake, J. A. M. R., & Estroff, L. A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001271 · Cited by 128
Metadata
- Authors
- Daudon, M., Frochot, V., Bazin, D., & Jungers, P.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Daudon, Michel
- Venue
- Drugs
- Published
- 2017-12-20
- Volume
- 78
- Issue
- 2
- Pages
- 163-201
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2781125041
- Cited by
- 191
- References
- 481
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 28 · 2023: 28 · 2022: 36 · 2021: 24 · 2020: 19 · 2019: 10 · 2018: 6 · 2017: 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Urology › Kidney Stones and Urolithiasis Treatments
- Health Sciences › Medicine › Nephrology › Nephrotoxicity and Medicinal Plants
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- drug-induced nephrolithiasis, crystalline nephropathy, kidney stones, urinary calculi, crystalluria, atazanavir, protease inhibitors, sulfadiazine, ceftriaxone, ephedrine, acute kidney injury, urine pH, calcium and vitamin D supplementation, carbonic anhydrase inhibitors, acetazolamide, topiramate, stone prevention, stone composition analysis
- MeSH terms
- Crystallization, Humans, Kidney Calculi, Risk Factors, Solubility, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions, Renal Elimination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. https://app.cochat.ai/papers/10.1007/s40265-017-0853-7
- The paper
- Daudon, M., Frochot, V., Bazin, D., & Jungers, P. (2018). Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs. https://doi.org/10.1007/s40265-017-0853-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.